Pavlova
Alla Viktorovna Pavlova, Novosibirsk RU
Patent application number | Description | Published |
---|---|---|
20130116319 | Agent for Treating Parkinson's Disease - The present invention relates to the use of 3-methyl-6-(1-methylethenyl)cyclohex-3-ene-1,2-diol, its isomers and derivatives, as a compound for Parkinson disease treatment, that can be used in medicine. The compound is highly active, low toxic and can be synthesized from available natural compound α-pinene. | 05-09-2013 |
Hanna Pavlova, Goleta, CA US
Patent application number | Description | Published |
---|---|---|
20090121712 | Dynamic nuclear polarization enhanced nuclear magnetic resonance of water under ambient conditions - A method and apparatus are provided for treating hydrated material in a fluid that contains water in which a stable nitroxide is attached to the hydrated material. A dynamic nuclear polarization process (DNP) is conducted on the hydrated material whereby to hyperpolarize the water. A polarization cell contains the hydrated material to obtain hyperpolarized water free from the nitroxide. The dynamic nuclear polarization process is conducted using components comprising a tunable, solid state high power X-band driver and an X-band resonator for microwave transmission to the hydrated material. The components can also include a radio-frequency nuclear magnetic resonance probe, a permanent magnet formed to receive the hydrated material, a portable nuclear magnetic resonance spectrometer, and an electron spin resonance detector. The components can be sized to be portable, and include electrical input and output and a lap-size hard-case with access to the electrical input and output. | 05-14-2009 |
20110150779 | DYNAMIC NUCLEAR POLARIZATION ENHANCED NUCLEAR MAGNETIC RESONANCE OF WATER UNDER AMBIENT CONDITIONS - A method and apparatus are provided for treating hydrated material in a fluid that contains water in which a stable nitroxide is attached to the hydrated material. A dynamic nuclear polarization process (DNP) is conducted on the hydrated material whereby to hyperpolarize the water. A polarization cell contains the hydrated material to obtain hyperpolarized water free from the nitroxide. The dynamic nuclear polarization process is conducted using components comprising a tunable, solid state high power X-band driver and an X-band resonator for microwave transmission to the hydrated material. The components can also include a radio-frequency nuclear magnetic resonance probe, a permanent magnet formed to receive the hydrated material, a portable nuclear magnetic resonance spectrometer, and an electron spin resonance detector. The components can be sized to be portable, and include electrical input and output and a lap-size hard-case with access to the electrical input and output. | 06-23-2011 |
Ludmila Pavlova, Moscow RU
Patent application number | Description | Published |
---|---|---|
20100069816 | Biocompatible devices, systems, and methods for reducing levels of proinflammatory or antiinflammatory stimulators or mediators in the blood - Devices, systems, and methods reduce levels of proinflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among proinflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of proinflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among proinflammatory or anti-inflammatory stimulators or mediators. | 03-18-2010 |
20100233673 | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products - Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems; and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators. | 09-16-2010 |
20110004152 | Biocompatible devices, systems, and methods for reducing levels of proinflammatory of antiinflammatory stimulators or mediators in the blood - Devices, systems, and methods reduce levels of proinflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among proinflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of proinflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among proinflammatory or anti-inflammatory stimulators or mediators. | 01-06-2011 |
20110097700 | Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood - Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators. | 04-28-2011 |
Maria N. Pavlova, Seattle, WA US
Patent application number | Description | Published |
---|---|---|
20080260744 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 10-23-2008 |
20090178153 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 07-09-2009 |
20110185439 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 07-28-2011 |
20110214189 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 09-01-2011 |
20130247233 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 09-19-2013 |
Maryana Z. Pavlova, Saint Petersburg, FL US
Patent application number | Description | Published |
---|---|---|
20110004031 | GLYCERIN PURIFICATION - Techniques are generally described herein for the purification of glycerin. Embodiments include, but are not limited to, methods, systems, and articles of manufacture. Other embodiments may also be disclosed and claimed. Some techniques described herein include adding methyl alcohol and acid to crude glycerin to form a solution, filtering the solution to remove at least one salt of the acid from the solution, separating the solution into a first layer of free fatty acids and a second layer of at least partially purified glycerin, and distilling off the methyl alcohol from second layer of the solution. The second layer may then undergo one or more additional operations including neutralizing, further filtering to remove an excess of the neutralizing agent, passing through a plurality of ion-exchange columns, deodorizing, and dewatering. | 01-06-2011 |
Natalia Sergeevna Pavlova, Cherepovets City RU
Patent application number | Description | Published |
---|---|---|
20160072953 | MANAGING PHONE NUMBERS IN A TELEPHONY SYSTEM - Techniques are described for managing phone numbers associated with a telephony system to reduce the likelihood that calls or transmissions directed to a subscriber or endpoint to which a phone number was previously assigned are received by a new subscriber or endpoint to which that number is reassigned. | 03-10-2016 |
Olga Pavlova, Moscow RU
Patent application number | Description | Published |
---|---|---|
20080200374 | MUTATIONAL DERIVATIVES OF MICROCIN J25 - Analogs of bacteriocidal peptide microcin J25 (MccJ25) are provided that have an amino acid sequence that differs from that of MccJ25 by having at least one amino acid substitution; and that inhibit bacterial cell growth with a potency at least equal to that of MccJ25. | 08-21-2008 |
Sarka Pavlova, Brno CZ
Patent application number | Description | Published |
---|---|---|
20150209354 | CASEIN KINASE 1 INHIBITORS FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC|LEUKEMIA - Medicaments for the treatment of the B-cell chronic lymphocytic leukemia, which are inhibitors of casein kinase 1. | 07-30-2015 |
Yelena Pavlova, Naantali FI
Patent application number | Description | Published |
---|---|---|
20130140155 | MEMS Switch Having Cantilevered Actuation - A MEMS switch comprises a top cantilevered conductor that moves downwardly. At least one first insulator layer is positioned below the top cantilevered conductor. At least one second insulator layer is positioned below the at least one first insulator layer such that at least one gap is formed between the top cantilevered conductor and the at least one second insulator layer. The gap has a thickness in the range 0.5 Å to 100 Å when the top cantilevered conductor is at rest. The thickness of the at least one gap decreases when the top cantilevered conductor is moved downwardly. At least one contact conductor is positioned below the top cantilevered conductor. The second insulator layer has at least one opening that exposes a conducting area of the at least one contact conductor within the second insulator layer. At least one actuation conductor is electrically insulated from the at least one contact conductor such that application of at least one actuation voltage to the at least one actuation conductor moves the top cantilevered conductor downwardly towards the at least one contact conductor for making an electrical connection between the top cantilevered conductor and the at least one contact conductor. | 06-06-2013 |
20130220783 | MEMS Switch Having One or More Vacuum Gaps - A MEMS switch comprises a top conductor and at least one first insulator layer having a lateral opening. The at least one first insulator layer hermetically seals the top conductor. At least one second insulator layer is positioned below the at least one first insulator layer such that at least one vacuum gap is formed within the lateral opening between the top conductor and the at least one second insulator layer. The at least one vacuum gap has a thickness in the range 0.5 Å to 100 Å when the top conductor is at rest. The thickness of the at least one vacuum gap varies when the top conductor is moved. The insulator layer has at least one opening that exposes a conducting area of at least one contact conductor within the second insulator layer. At least one actuation conductor that is electrically insulated from the at least one contact conductor such that application of at least one actuation voltage to the at least one actuation conductor moves the at least one contact conductor and the top conductor closer to each other within the at least one vacuum gap. | 08-29-2013 |
Yelena Vasiljevna Pavlova, Naantali FI
Patent application number | Description | Published |
---|---|---|
20130152694 | SENSOR WITH VACUUM CAVITY AND METHOD OF FABRICATION - A MEMS pressure sensor device comprises a sensor element positioned on top of a carrier and a cavity. The sensor element hermetically seals the cavity. An electrode is coupled to the cavity that forms a pressure transducer together with the sensor element. The cavity is created by a density changing material. | 06-20-2013 |